Figure 2From: Paclitaxel-resistant advanced recurrent breast cancer: a case of partial response due to addition of bevacizumab to paclitaxel therapy: a case reporta and b (CT from April 2012). Three months after bevacizumab and weekly PTX were begun, the left axillary lymph node reduced in size to 1.4 cm and the lung metastases also became smaller.Back to article page